In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-30. (Canceled)

31. (Currently Amended) A method for administering high dosages of topiramate ~~an active agent~~ to a subject comprising:

~~A~~administering a high dose osmotic dosage ~~from~~ form to the subject wherein the dosage form comprises:

(a) a capsule shaped tablet core comprising a plurality of layers wherein a composition containing about 50-60% of ~~an active agent~~ topiramate, about 5-15% of a structural polymer carrier and about 15-40% of a solubilizing surfactant is contained in at least one layer and at least one other layer comprises a suitable fluid-expandable polymer;

(b) a semipermeable membrane at least partially surrounding the capsule shaped tablet core to form a compartment having an osmotic gradient to drive fluid from an external fluid environment contacting the semipermeable membrane into the compartment; and

(c) an orifice formed through the semipermeable membrane and into the capsule shaped tablet core to permit the active agent to be released from within the compartment into the external fluid environment;

wherein the dosage form releases the ~~active agent~~ topiramate at a substantially ascending release rate for a prolonged period of time.

32. (Canceled)

33. (Currently Amended) The method according to Claim ~~32~~31, wherein the capsule shaped tablet core comprises two layers and the topiramate is contained within a first layer and the fluid-expandable polymer is contained within a second layer and the orifice is formed through the semipermeable membrane adjacent the first layer.

34. (Currently Amended) The method according to Claim ~~32~~31, wherein the capsule shaped tablet core comprises three layers and a portion of the topiramate is contained within a first layer and the remaining portion of the topiramate is contained within a second layer, wherein the portion of topiramate contained within the first layer is less than the portion of topiramate contained within the second layer, and wherein the fluid-expandable polymer is contained within a third layer and the orifice is formed through the semipermeable membrane adjacent the first layer.

35. (Original) The method according to Claim 34, wherein the proportion of topiramate contained within the first layer to the topiramate contained within the second layer is within the range of about 1.0:2.0 to about 1.0:1.2.

36. (Original) The method according to Claim 34, wherein the proportion of topiramate contained within the first layer to the topiramate contained within the second layer is within the range of about 1.0:1.5 to about 1.0:1.2.

37. (Original) The method according to Claim 34, wherein the proportion of topiramate contained within the layers to the solubilizing surfactant is within the range of about 0.5:1.0 to about 2.0:1.0.

Claims 38-47 (Canceled)

48. (Currently Amended) ~~The~~ A high dose osmotic dosage form ~~according to Claim 47~~ comprising:

(a) a capsule shaped tablet core containing a plurality of layers wherein ~~the topiramate is contained in~~ at least one layer comprises about 50-60% of topiramate, about 5-15% of a structural polymer carrier and about 15-40% of a solubilizing surfactant and at least one other layer comprises a suitable fluid-expandable polymer;

(b) a semipermeable membrane surrounding the capsule shaped tablet core to form a compartment having an osmotic gradient to drive fluid from an external fluid environment contacting the semipermeable membrane into the compartment; and

(c) an orifice formed through the semipermeable membrane and into the capsule shaped tablet core to permit topiramate to be released from within the compartment into the external fluid environment~~.~~;

which provides a substantially ascending rate of release of the topiramate for a prolonged period of time.

49. (Original) The dosage form according to Claim 48, wherein the capsule shaped tablet core comprises two layers and the topiramate is contained within a first layer and the fluid-expandable polymer is contained within a second layer and the orifice is formed through the semipermeable membrane adjacent the first layer.

50. (Original) The dosage form according to Claim 48, wherein the capsule shaped tablet core comprises three layers and a portion of the topiramate is contained within a first layer and the remaining portion of the topiramate is contained within a second layer, wherein the portion of topiramate contained within the first layer is less than the portion of topiramate contained within the second layer, and wherein the fluid-expandable polymer is contained within a third layer and the orifice is formed through the semipermeable membrane adjacent the first layer.

51. (Original) The dosage form according to Claim 50, wherein the proportion of topiramate contained within the first layer to the topiramate contained within the second layer is within the range of about 1.0:2.0 to about 1.0:1.2.

52. (Original) The dosage form according to Claim 50, wherein the proportion of topiramate contained within the first layer to the topiramate contained within the second layer is within the range of about 1.0:1.5 to about 1.0:1.2.

53. (Original) The dosage form according to Claim 50, wherein the proportion of topiramate contained within the layers to the solubilizing surfactant is within the range of about 0.5:1.0 to about 2.0:1.0.

54. (New) The dosage form as in Claim 48, wherein the structural polymer carrier is selected from the group consisting Polyox® N80; Polyox® N10; Maltrin M100; polyvinylpyrrolidone (PVP) 12PF; PVP K2932; Klucel EF and Kollidon VA64.

55. (New) The dosage form as in Claim 48, wherein the structural polymer carrier is Polyox® N80.

56. (New) The dosage form as in Claim 48, wherein the solubilizing surfactant is selected from the group consisting of polyethylene glycol (PEG) 3350; PEG 8K; Kollidon K90; Pluronic F 68, F87, F127, F108; Myrj 52S; and PVP K2939.

57. (New) The dosage form as in Claim 48, wherein the solubilizing surfactant is Myrj 52S.

58. (New) The dosage form as in Claim 48, wherein the topiramate is present in an amount equal to about 55%; the structural polymer carrier is Polyox® N80 and is present in an amount equal to about 11.5%; and the solubilizing surfactant is Myrj 52S and is present in an amount equal to about 30%.

59. (New) The method as in Claim 31, wherein the structural polymer carrier is selected from the group consisting Polyox® N80; Polyox® N10; Maltrin M100; polyvinylpyrrolidone (PVP) 12PF; PVP K2932; Klucel EF and Kollidon VA64.

60. (New) The method as in Claim 31, wherein the structural polymer carrier is Polyox® N80.

61. (New) The method as in Claim 31, wherein the solubilizing surfactant is selected from the group consisting of polyethylene glycol (PEG) 3350; PEG 8K; Kollidon K90; Pluronic F 68, F87, F127, F108; Myrj 52S; and PVP K2939.

62. (New) The method as in Claim 31, wherein the solubilizing surfactant is Myrj 52S.

63. (New) The method as in Claim 31, wherein the topiramate is present in an amount equal to about 55%; the structural polymer carrier is Polyox® N80 and is present in an amount equal to about 11.5%; and the solubilizing surfactant is Myrj 52S and is present in an amount equal to about 30%.